Credentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple Myeloma

Project: Research project

Project Details


Project Narrative Thalidomide and related drugs Lenalidomide and Pomalidomide (IMiDs) are very active in the treatment of multiple myeloma, but their clinical use remains mostly empirical because of lack of proper model systems that allow studying their complex effects on the tumor and on the immune system. To overcome this translational need we have generated a novel transgenic mouse model expressing the cellular receptor for these drugs and propose to validate it its use for understanding how IMiDs work in human with the ultimate goal to inform clinical practice.
Effective start/end date12/7/1811/30/22


  • National Cancer Institute: $341,752.00
  • National Cancer Institute: $379,725.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.